RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Asia stocks slide as US-Iran strikes batter risk appetite Oil prices surge after US-Israel strikes on Iran, trim early gains Gold prices jump 2% amid widening US-Israel conflict with Iran Middle East tensions rise as Iran promises retaliation (South Africa Philippines Nigeria) RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause By Investing.com Analyst Ratings Published 03/02/2026, 01:31 AM RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause 0 AARD -0.08% Investing.com - RBC Capital downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) to Sector Perform from Outperform and cut its price target to $6.00 from $18.00. The stock currently trades at $12.49, well above the new target but below the analyst high target of $47. The downgrade follows Aardvark’s announcement Friday evening of a voluntary pause of its ongoing Phase III study of lead drug ARD-101 for Prader-Willi syndrome due to cardiac observations in a separate study of healthy subjects. RBC Capital said it had the chance to speak with management following the announcement. The firm noted that clean safety was seen at therapeutic doses, which may still allow a path forward for the drug. The firm said timelines will likely be pushed back meaningfully as the company engages with the FDA on next steps. The development adds a layer of uncertainty to what was considered the lower-risk element of the program’s profile, its acute safety. RBC Capital said it is stepping to the sidelines pending further clarity on the situation.The clinical pause comes as Aardvark maintains a strong balance sheet with a current ratio of 12.03 and holds more cash than debt, though InvestingPro notes the company is quickly burning through cash with negative free cash flow of $45 million. The platform’s Fair Value analysis suggests the stock is slightly overvalued at current levels, with 9 additional ProTips available to subscribers. In other ...